Company Filing History:
Years Active: 2004-2020
Title: Kathryn C. Zoon: Innovator in Cancer Treatment
Introduction
Kathryn C. Zoon is a prominent inventor based in Kensington, MD (US). She has made significant contributions to the field of cancer treatment, particularly through her innovative research and patented inventions. With a total of 3 patents, her work focuses on utilizing specific combinations of biological agents to combat ovarian cancer.
Latest Patents
One of her latest patents involves a synergistic combination of interleukin-4 (IL-4), interferon gamma, and interferon alpha for treating ovarian cancer. This patent discloses methods and compositions for treating subjects with cancer, specifically targeting cells that express the IL-4 receptor (IL-4R). The compositions may include a chimeric molecule that binds to IL-4R, along with a toxic moiety, interferon alpha (IFN-α), and interferon gamma (IFN-γ). Additionally, the methods may involve administering monocytes to enhance treatment efficacy.
Another notable patent from Kathryn C. Zoon focuses on hybrid human interferon-α polypeptides and their corresponding nucleic acid molecules. This invention provides pharmaceutical compositions that utilize these peptides to treat viral diseases and regulate cell growth, showcasing her commitment to advancing medical science.
Career Highlights
Kathryn C. Zoon is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. Her work at this esteemed institution has allowed her to contribute to groundbreaking research in the field of oncology and immunology.
Collaborations
Throughout her career, Kathryn has collaborated with notable colleagues, including Renqiu Hu and Mark P. Hayes. These partnerships have further enriched her research and expanded the impact of her inventions.
Conclusion
Kathryn C. Zoon's innovative work in cancer treatment exemplifies the vital role of inventors in advancing medical science. Her patents reflect a deep commitment to improving therapeutic options for patients facing ovarian cancer and other diseases.